WeVote
Log In

Bill

Bill

A 692

Makes technical changes to certain provisions requiring epinephrine auto-injector devises to be made available in places of public assembly

2025 Regular Session Introduced by Linda Rosenthal

A 692 makes technical edits to clarify the availability of epinephrine auto-injectors in places of public assembly, aligning Assembly and Senate language; no new mandates.

SIGNED CHAP.22
0
WeVote Research Nonpartisan
Bill Summary · A 692

Legislative Summary — Assembly Bill A 692

Overview

  • Bill Number: A 692
  • Title: Makes technical changes to certain provisions requiring epinephrine auto-injector devices to be made available in places of public assembly
  • Primary Sponsor: Linda Rosenthal
  • Status: Enacted as Chapter 22 (SIGNED into law on February 14, 2025)
  • Introduced: January 8, 2025
  • Related companion: S 748 (Senate)

Purpose and Intent

A 692 is a technical amendments measure intended to clarify and streamline existing requirements that epinephrine auto-injectors be available in places of public assembly. The bill does not introduce new mandates or broaden access beyond the existing framework; rather, it refines the statutory language to improve clarity and consistency in how the requirements are implemented and enforced.

Key Provisions and Changes

  • Makes technical edits to current law governing the availability of epinephrine auto-injectors in places of public assembly.
  • Aims to clarify terminology, definitions, and compliance expectations to reduce ambiguity for venues and other covered locations.
  • Aligns the Assembly and Senate language through its cross-reference to the companion Senate bill (S 748), ensuring consistency in the statutory framework.

Note: The available legislative record emphasizes “technical changes” rather than substantive expansions or new mandates. The specific textual changes are contained in the final enacted version (Chapter 22).

Who is Affected

  • Operators and managers of places of public assembly (e.g., event venues, public facilities) responsible for complying with epinephrine auto-injector availability requirements.
  • Public health authorities and compliance officers tasked with enforcing the relevant provisions.
  • Potentially, staff or vendors involved in stocking, maintaining, or administering epinephrine auto-injectors in covered locations.

Timeline and Status

  • 2025-01-08: Referred to Health (initial referral)
  • 2025-01-14 to 01-21: Passed Assembly (including rules committee actions and readings)
  • 2025-01-21: Delivered to Senate; referred to Rules
  • 2025-02-03: Substituted for S748; passed Senate; third reading
  • 2025-02-12: Delivered to Governor
  • 2025-02-14: Signed into law as Chapter 22

Legislative History and Related Measures

  • Companion bill: S 748 (Senate)
  • A 692 passed through the standard late-January to February 2025 legislative process, culminating in gubernatorial signing on February 14, 2025.
  • The relation to S 748 indicates alignment between Assembly and Senate texts prior to enactment.

Notes

  • The summary reflects published legislative actions and the bill’s stated aim as a technical clarifying measure; the enacted text will detail the precise edits and any effective date provisions.
  • No new funding or penalties are indicated in the summary of the bill’s stated purpose.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.